These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 25060414)

  • 1. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).
    Vaduganathan M; Dei Cas A; Mentz RJ; Greene SJ; Khan S; Subacius HP; Chioncel O; Maggioni AP; Konstam MA; Senni M; Fonarow GC; Butler J; Gheorghiade M;
    Am J Cardiol; 2014 Sep; 114(5):743-50. PubMed ID: 25060414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction.
    Suzuki S; Motoki H; Kanzaki Y; Maruyama T; Hashizume N; Kozuka A; Yahikozawa K; Kuwahara K
    ESC Heart Fail; 2020 Oct; 7(5):2752-2761. PubMed ID: 32592265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
    Ferreira JP; Zannad F; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Jamal W; Steubl D; Schueler E; Packer M
    J Am Coll Cardiol; 2021 Mar; 77(11):1397-1407. PubMed ID: 33736821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
    Cooper LB; Lippmann SJ; Greiner MA; Sharma A; Kelly JP; Fonarow GC; Yancy CW; Heidenreich PA; Hernandez AF
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29275368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure.
    Beldhuis IE; Damman K; Pang PS; Greenberg B; Davison BA; Cotter G; Gimpelewicz C; Felker GM; Filippatos G; Teerlink JR; Metra M; Voors AA; Ter Maaten JM
    Eur J Heart Fail; 2023 Sep; 25(9):1584-1592. PubMed ID: 37462255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M;
    Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
    Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
    Vaduganathan M; Claggett BL; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Desai AS; Jhund PS; Viswanathan P; Bomfim Wirtz A; Schloemer P; Lay-Flurrie J; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2024 Jun; 26(6):1324-1333. PubMed ID: 38742248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of the Use of Mineralocorticoid Receptor Antagonists in Patients With Left Ventricular Dysfunction Post-ST-Segment-Elevation Myocardial Infarction.
    Wong EC; Fordyce CB; Wong G; Lee T; Perry-Arnesen M; Mackay M; Singer J; Cairns JA; Turgeon RD
    J Am Heart Assoc; 2021 Jul; 10(14):e019167. PubMed ID: 34227405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
    Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
    Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
    JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Ferreira JP; Rossignol P; Machu JL; Sharma A; Girerd N; Anker SD; Cleland JG; Dickstein K; Filippatos G; Hillege HL; Lang CC; Ter Maaten JM; Metra M; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Voors A; Zannad F
    Eur J Heart Fail; 2017 Oct; 19(10):1284-1293. PubMed ID: 28580625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.
    Bruno N; Sinagra G; Paolillo S; Bonomi A; Corrà U; Piepoli M; Veglia F; Salvioni E; Lagioia R; Metra M; Limongelli G; Cattadori G; Scardovi AB; Carubelli V; Scrutino D; Badagliacca R; Guazzi M; Raimondo R; Gentile P; Magrì D; Correale M; Parati G; Re F; Cicoira M; Frigerio M; Bussotti M; Vignati C; Oliva F; Mezzani A; Vergaro G; Di Lenarda A; Passino C; Sciomer S; Pacileo G; Ricci R; Contini M; Apostolo A; Palermo P; Mapelli M; Carriere C; Clemenza F; Binno S; Belardinelli R; Lombardi C; Perrone Filardi P; Emdin M; Agostoni P
    ESC Heart Fail; 2018 Jun; 5(3):267-274. PubMed ID: 29397584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
    Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
    JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Mineralocorticoid Receptor Antagonist Use With All-Cause Mortality and Hospital Readmission in Older Adults With Acute Decompensated Heart Failure.
    Yaku H; Kato T; Morimoto T; Inuzuka Y; Tamaki Y; Ozasa N; Yamamoto E; Yoshikawa Y; Kitai T; Taniguchi R; Iguchi M; Kato M; Takahashi M; Jinnai T; Ikeda T; Nagao K; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Toyofuku M; Seko Y; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Sato Y; Kuwahara K; Kimura T;
    JAMA Netw Open; 2019 Jun; 2(6):e195892. PubMed ID: 31225889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M;
    Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.